我们重视您的隐私
我们使用 Cookie 分析网站流量并改善您的体验。请参阅我们的隐私政策。
相关临床试验
1
0 进行中
药物批准
112
批准总数
监管机构
监管机构数
成立时间
N/A
已完成
100.0%
FDA
Food and Drug Administration
- GlaxoSmithKline discontinued its popular asthma inhaler Flovent in December 2023 to avoid paying an estimated $367.6 million in additional Medicaid rebates under new federal anti-price gouging provisions. - The discontinuation forced families to switch to more expensive alternatives, with 36% of families reporting difficulty paying for replacements and 30% struggling with insurance coverage according to a Boston Children's Hospital survey. - Following a two-year Senate investigation led by Sen. Maggie Hassan, GSK agreed to allow competitor Glenmark Specialty SA to sell a lower-cost generic version starting this month. - The FDA has approved a generic version of Flovent that should restore affordable access to the critical pediatric asthma medication for the 4.6 million children diagnosed with asthma nationwide.
